Cohen Klingenstein LLC Has $779,000 Stock Position in Haleon plc (NYSE:HLN)

Cohen Klingenstein LLC cut its holdings in shares of Haleon plc (NYSE:HLN) by 8.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 81,613 shares of the company’s stock after selling 7,644 shares during the period. Cohen Klingenstein LLC’s holdings in Haleon were worth $779,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Brooklyn Investment Group increased its holdings in Haleon by 168.1% during the 4th quarter. Brooklyn Investment Group now owns 6,080 shares of the company’s stock worth $58,000 after purchasing an additional 3,812 shares in the last quarter. Merit Financial Group LLC purchased a new position in shares of Haleon during the fourth quarter valued at approximately $152,000. Procyon Advisors LLC grew its holdings in Haleon by 41.3% during the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company’s stock worth $2,196,000 after buying an additional 67,329 shares in the last quarter. Ritholtz Wealth Management raised its position in Haleon by 128.1% in the 4th quarter. Ritholtz Wealth Management now owns 59,214 shares of the company’s stock valued at $565,000 after buying an additional 33,249 shares during the last quarter. Finally, Heritage Family Offices LLP lifted its stake in Haleon by 7.4% during the 4th quarter. Heritage Family Offices LLP now owns 91,314 shares of the company’s stock valued at $871,000 after acquiring an additional 6,311 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Performance

NYSE HLN opened at $9.24 on Friday. The company’s 50 day simple moving average is $9.54 and its two-hundred day simple moving average is $9.69. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The stock has a market capitalization of $41.80 billion, a PE ratio of 27.16, a P/E/G ratio of 2.52 and a beta of 0.29.

Wall Street Analyst Weigh In

HLN has been the subject of several recent analyst reports. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Morgan Stanley cut Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Haleon currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.